AngioDynamics (NASDAQ:ANGO) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of AngioDynamics (NASDAQ:ANGO) in a research report report published on Tuesday,Benzinga reports. HC Wainwright currently has a $14.00 target price on the medical instruments supplier’s stock.

Separately, Canaccord Genuity Group dropped their target price on AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a report on Friday, October 4th.

AngioDynamics Stock Up 3.0 %

ANGO stock opened at $8.89 on Tuesday. AngioDynamics has a 52 week low of $5.26 and a 52 week high of $9.42. The firm has a market capitalization of $361.24 million, a P/E ratio of -1.46 and a beta of 0.68. The company has a fifty day simple moving average of $6.88 and a two-hundred day simple moving average of $6.90.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.04. The firm had revenue of $67.50 million for the quarter, compared to analysts’ expectations of $67.93 million. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The business’s revenue was down 14.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.12) EPS. As a group, analysts anticipate that AngioDynamics will post -0.41 EPS for the current year.

Insider Buying and Selling

In other AngioDynamics news, CEO James C. Clemmer bought 20,000 shares of the company’s stock in a transaction on Monday, October 7th. The stock was acquired at an average price of $6.03 per share, for a total transaction of $120,600.00. Following the completion of the transaction, the chief executive officer now directly owns 681,582 shares of the company’s stock, valued at approximately $4,109,939.46. This represents a 3.02 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have bought 22,568 shares of company stock valued at $135,847 in the last ninety days. 5.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On AngioDynamics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Quarry LP grew its position in AngioDynamics by 75.1% in the 2nd quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier’s stock valued at $37,000 after acquiring an additional 2,594 shares during the last quarter. CWM LLC grew its holdings in shares of AngioDynamics by 981.3% in the third quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier’s stock worth $76,000 after purchasing an additional 8,832 shares during the last quarter. Mackenzie Financial Corp purchased a new position in AngioDynamics in the 2nd quarter worth about $80,000. Wealth Enhancement Advisory Services LLC purchased a new position in AngioDynamics in the 3rd quarter worth about $86,000. Finally, AE Wealth Management LLC bought a new stake in AngioDynamics during the 2nd quarter valued at about $87,000. 89.43% of the stock is currently owned by hedge funds and other institutional investors.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.